Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors

Summary

A phase Ia, multicenter, open and dose-increasing study of DP303c to evaluate the safety , pharmacokinetics, immunogenicity and antitumor activity of subjects with HER2-positive advanced solid tumors.

Timeline

Start

2019-11

Primary completion

2021-06

Completion

2021-06

Publications

• Zhang J, Du Y, Meng Y, Liu X, Mu Y, Liu Y, Shi Y, Wang J, Zang A, Gu S, Liu T, Zhou H, Guo H, Xiang S, Zhang X, Wu S, Qi H, Li M, Hu X. First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors. NPJ Precis Oncol. 2024 Sep 12;8(1):200. doi: 10.1038/s41698-024-00687-7.

Drugs

Indications